Researchers at the National Cancer Institute have discovered a new way in which PARP inhibitors block cancer cell growth. They also discovered that three experimental PARP inhibitors vary widely in their ability to kill cancer cells. PARP inhibitors are a class of drugs that have shown promising results against ovarian cancer in women with BRCA1 and BRCA2 gene mutations. According to study author Dr. Junko Murai, the findings “suggest that clinicians who use PARP inhibitors in clinical trials should carefully choose their drug, because we now suspect results may differ, depending upon the PARP inhibitor used.”
Results of the study were published in Cancer Research.
Click here for more information.